Adil Daud, MD, on the Importance of Testing Patients with Melanoma for BRAF Mutations
Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.
Jeffrey Weber, MD, PhD, Describes Unmet Needs for Patients with Melanoma
Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.
Hussein Tawbi, MD, PhD, Discusses Results From the COMBI-AD Trial
Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.
Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments
CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.
Kunal Rai, PhD, Discusses Genomic Alterations in Melanoma Therapy
The MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.
Richard White, MD, PhD, Discusses His Research into Why Melanoma Metastasizes
The Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.
Sancy Leachman, MD, PhD, Discusses Her Early-Detection Outreach Effort for Melanoma
Sancy Leachman, MD, PhD, discusses her outreach effort titled “War on Melanoma” at the 16th International Congress of the Society for Melanoma Research.
Poulikos Poulikakos, PhD, on Combining Targeted Therapy and Immunotherapy in Melanoma
Poulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Study Moves the Needle for Melanoma Patients with Rare BRAF Mutations
BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.
Incidence of Non-Melanoma Skin Cancer Tallies Biggest Change From 2016 to 2017
The Global Burden of Disease 2017 study found non-melanoma skin cancer to be the biggest increase in incidence worldwide.
Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?
A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
Standardization Arrives for Neoadjuvant Trials in Melanoma
The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.
T-VEC Plus Pembrolizumab Combo Shows Activity in Advanced Melanoma
The combination of the attenuated oncolytic virus talimogene laherparepvec (T-VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well-tolerated by advanced melanoma patients.
Cobimetinib/Vemurafenib Improves Survival in BRAF-Mutated Melanoma
A combination of cobimetinib and vemurafenib prolongs overall survival in melanoma patients with BRAF V600 mutations.
Epacadostat/Pembrolizumab Combo Shows Activity in Advanced Melanoma
The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.
Low-Dose Ipilimumab/Pembrolizumab Reduces Toxicity in Advanced Melanoma
A combination of pembrolizumab and low-dose ipilimumab appears to be active and to have a better safety profile than a combination of nivolumab and full-dose ipilimumab in advanced melanoma patients.
Pembrolizumab Induces Responses in Melanoma Patients With Brain Mets
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.
Older Men More Likely to Develop Multiple Primary Melanomas
Older men are more likely to be diagnosed with multiple primary melanomas and have worse cutaneous malignant melanoma–specific survival than men with a single primary melanoma.
Nivolumab Shows Promise in Mucosal Melanoma
Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.
Immune Expression in Sentinel Lymph Node Biopsies Helps Predict Melanoma Outcomes
The expression of immune markers and T-cell subsets can help predict outcomes of sentinel lymph node–positive melanoma patients, according to a new study.
Checkpoint Inhibitors Improve QoL in Melanoma Survivors
The checkpoint inhibitors pembrolizumab and nivolumab not only prolong survival in advanced melanoma patients but also maintain health-related quality of life.
Melanoma Patients Suffer Side Effects of Checkpoint Inhibitors, Yet Maintain QoL
Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health-related quality of life.
2 Clarke Drive Cranbury, NJ 08512